- Born:
- June 2, 1949, Baltimore, Md., U.S. (age 77)
- Notable Works:
- āThe Genetics of Cancerā
- Subjects Of Study:
- APC
- cancer
- dicyclohexylcarbodiimide
- genetics
- p53
Bert Vogelstein
-
Who is Bert Vogelstein?
Bert Vogelstein (born in Baltimore, Maryland, on June 2, 1949) is an American oncologist celebrated for his seminal work on the genetics of cancer. His research elucidated the life history of a tumor cell, identifying genes that, when damaged, give rise to the disease. He discovered that tumors develop due to accumulated mutations in proto-oncogenes, tumor-suppressor genes, and mismatch repair genes. Vogelstein's work led to new diagnostic tests for colon cancer and the use of anaerobic microbes in tumor treatment. He was elected to the American Academy of Arts and Sciences and the National Academy of Sciences in 1992.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is an oncologist?
An oncologist is a doctor who specializes in oncology, a branch of medicine focused on the prevention, diagnosis, treatment, and study of cancer.
Bert Vogelstein (born in Baltimore, Md., U.S., on June 2, 1949) is an American oncologist celebrated for his seminal work on the genetics of cancer. His research elucidated how tumors develop from accumulated mutations in proto-oncogenes, tumor-suppressor genes, and mismatch repair genes. Vogelstein's work led to new diagnostic tests for colon cancer and the use of anaerobic microbes in tumor treatment.
4 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What field of cancer research is Bert Vogelstein known for?
Bert Vogelstein is an American oncologist celebrated for his pioneering work in the genetics of cancer. His research focuses on identifying genes that, when damaged, can lead to the development of cancer. Specifically, Vogelstein's work has helped to clarify that tumors arise from the accumulation of mutations in proto-oncogenes, tumor-suppressor genes, and mismatch repair genes. His work led to the development of diagnostic tests for colon cancer.
3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is Bert Vogelsteinās major discovery about how cancer develops?
Bert Vogelstein, an American oncologist, is renowned for his work on the genetics of cancer. His research revealed that tumors arise from the accumulation of mutations in proto-oncogenes, tumor-suppressor genes, and mismatch repair genes. He identified mutated forms of tumor-suppressor genes, including p53, DCC, and APC, in colon cancer cells. His work also showed that mutations in the p53 gene were involved in a majority of cancerous tumors. Vogelstein's discoveries led to new diagnostic tests for colon cancer and the use of anaerobic microbes in tumor treatment.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How did Bert Vogelsteinās research change how scientists understand cancer genes?
Bert Vogelstein's research elucidated the genetic history of tumor cells, particularly in colon cancer. His work revealed that tumors arise from accumulated mutations in proto-oncogenes, tumor-suppressor genes, and mismatch repair genes. This understanding underscored that cancer development isn't triggered by a single gene mutation but by a sequence of genetic changes. His work led to new diagnostic tests and potential treatments for colon cancer.
3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
Why is Bert Vogelsteinās work important for developing cancer treatments?
Bert Vogelstein's work is important for developing cancer treatments because he elucidated the life history of a tumor cell. His research identified that tumors develop due to sequential mutations in proto-oncogenes, tumor-suppressor genes, and mismatch repair genes. This made it clear that cancer cells were normal cells transformed into unruly mavericks. On a practical level, Vogelstein's work led to diagnostic tests for colon cancer that promised to greatly reduce deaths from the disease. He later pioneered the use of anaerobic microbes in the treatment of tumors.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
Bert Vogelstein (born June 2, 1949, Baltimore, Md., U.S.) is an American oncologist known for his groundbreaking work on the genetics of cancer.
Vogelstein was raised in Baltimore and attended a private middle school from which he was often truant, preferring to teach himself by reading at the public library. He received a bachelorās degree in mathematics from the University of Pennsylvania in 1970. Vogelstein then briefly pursued a masterās degree in mathematics but instead proceeded to earn a medical degree from the Johns Hopkins University School of Medicine in Baltimore in 1974. He spent the following two years completing his residency in pediatrics at Johns Hopkins Hospital. His experiences working with young cancer patients there influenced his decision to join the National Cancer Institute as a research associate (1976ā78). In 1978 he was appointed assistant professor of oncology at Johns Hopkins University.
Although scientists knew that cancer cells were normal cells transformed into unruly mavericks, the reasons for the transformation were unclear until Vogelstein took on the task of elucidating the life history of a tumour cell. In 1982 Vogelstein set out to apply his laboratory expertise to the study of colon cancer. His goal was to identify the genes that, when damaged or defective, give rise to the disease. Analyzing DNA from the cells of colon tumours, he and colleagues found that a particular gene was present in a mutated form in more than one-half of all the tumours they studied. The gene in question, called K-ras, belongs to the class known as oncogenes (i.e., cancer-inducing genes). In their normal form, as proto-oncogenes, these genes stimulate cells to replicate when necessary. However, when damaged they may signal the cell to divide ceaselessly. Evidence suggested that a single mutated gene could not trigger the development of cancer. Vogelstein suspected that a defect in another class of growth regulators, called tumour-suppressor genes for their role in preventing uncontrolled cell proliferation, might also be involved. By 1988 his lab had located some of the most frequent chromosomal deletions in colorectal tumours. He became a full professor of oncology at Johns Hopkins in 1989.
Again studying DNA from colon cancer cells, Vogelstein eventually identified three tumour-suppressor genes, p53 (1989), DCC (1990), and APC (1991), mutated forms of which were found in the tumour cells. Further research on p53 showed that mutations in this gene were involved not only in colon cancer but in a host of other malignancies; in fact, p53 was implicated in more than 50 percent of all cancerous tumours. Data from Vogelsteinās laboratory also provided evidence of still another class of cancer-causing genes, called mismatch repair (MMR) genes, whose normal function is to identify and repair defective DNA segments. Vogelsteinās research made it clear that tumours develop as a result of the sequential accumulation of mutations in proto-oncogenes, tumour-suppressor genes, and mismatch repair genes. On a practical level, his work led to the development of diagnostic tests for colon cancer that promised to greatly reduce deaths from the disease. He later pioneered the use of anaerobic microbes in the treatment of tumours.
In 1992 Vogelstein was elected to the American Academy of Arts and Sciences and the National Academy of Sciences. That year he also received a joint appointment in molecular biology and genetics at Johns Hopkins. In 1995 he became a Howard Hughes Medical Institute investigator and in 1998 was appointed to an additional post in pathology at Johns Hopkins.
In addition to publishing hundreds of articles in professional journals, Vogelstein cowrote The Genetics of Cancer (1997) with American oncologist Kenneth Kinzler, one of his former research assistants and later a full professor at Johns Hopkins. Vogelstein was awarded the 1997 William Beaumont Prize for his work on the genetics of cancer.